Dosing & Uses
Dosage Forms & Strengths
topical cream
- 0.3%
Plaque Psoriasis
Indicated for plaque psoriasis, including intertriginous areas
Apply once daily to affected areas and rub in completely
Wash hands after application, unless application is for treatment of hands
Dosage Forms & Strengths
topical cream
- 0.3%
Plaque Psoriasis
Indicated for plaque psoriasis, including intertriginous areas, in patients aged ≥12 years
<12 years: Safety and efficacy not established
≥12 years
- Apply once daily to affected areas and rub in completely
- Wash hands after application, unless application is for treatment of hands
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
1-10%
Diarrhea (3.1%)
Headache (2.4%)
Insomnia (1.4%)
Nausea (1.2%)
Application site pain (1%)
Upper respiratory tract infection (1%)
Urinary tract infection (1%)
Warnings
Contraindications
Moderate-to-severe liver impairment (Child-Pugh B or C)
Cautions
Hepatic impairment
- Contraindicated with moderate-to-severe impairment (Child-Pugh B or C)
- No studies were conducted with topical roflumilast in patients with hepatic impairment; however, oral roflumilast 250 mcg/day for 14 days was studied in mild-to-moderate hepatic impairment (Child-Pugh A and B)
- AUC of roflumilast and roflumilast N-oxide were increased by 51% and 24%, respectively, in Child-Pugh A and by 92% and 41%, respectively, in Child-Pugh B, as compared to age-, weight-, and gender-matched healthy individuals
- Peak plasma concentration of roflumilast and roflumilast N-oxide were increased by 3% and 26%, respectively, in Child-Pugh A and by 26% and 40%, respectively, in Child-Pugh B, as compared to healthy individuals
Drug interaction overview
- No formal drug-drug interaction studies were conducted with topical roflumilast
-
CYP Inhibitors
- Caution, monitor
- Coadministration of roflumilast with systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (eg, erythromycin, ketoconazole, fluvoxamine, cimetidine) may increase roflumilast systemic exposure
-
Oral contraceptives
- Caution, monitor
- Coadministration of roflumilast with oral contraceptives containing ethinyl estradiol may increase roflumilast systemic exposure
Pregnancy & Lactation
Pregnancy
There are no randomized clinical trials of oral or topical roflumilast in pregnant females
Animal studies
- Oral administration to pregnant rats and rabbits during organogenesis produced no fetal structural abnormalities at doses up to 9 and 8 times the maximum recommended human dose (MRHD), respectively
- Roflumilast induced post-implantation loss in rats at oral doses ≥3x MRHD
- Roflumilast induced stillbirth and decreased pup viability in mice at oral doses 5x and 15x MRHD, respectively
- Shown to adversely affect pup post-natal development when dams were treated with oral dose 15x MRHD during pregnancy and lactation periods in mice
Clinical considerations
- Do not use during labor and delivery
- There are no human studies that have investigated effects on preterm labor or labor at term; however, animal studies showed roflumilast PO disrupted labor and delivery process in mice
Lactation
Data are not available regarding presence in human milk, effects on breastfed infants, or effects on milk production
Roflumilast and/or its metabolites are excreted into the milk of lactating rats; when a drug is present in animal milk, it is likely that to be present in human milk
Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for treatment and any potential adverse effects on the breastfed infant
Clinical considerations
- Minimize potential exposure to breastfeeding infants via breast milk by applying to smallest area of skin and for the shortest duration possible
- Advise breastfeeding women not to apply cream directly to the nipple and areola to avoid direct infant exposure
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of phosphodiesterase (PDE)-4
Inhibition of PDE4 (a major cyclic 3′,5′-adenosine monophosphate (cyclic AMP) metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP
Specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined
Absorption
Following application of mean BSA 26.8% and 13% in adults (n = 18) and adolescents (n = 6) respectively, plasma concentrations were quantifiable in all but 2 individuals at Day 15
AUC (adults): 72.7 h⋅ng/mL (roflumilast); 628 h⋅ng/mL (N-oxide metabolite)
AUC (adolescents): 25.1 h⋅ng/mL (roflumilast); 140 h⋅ng/mL (N-oxide metabolite)
Distribution
Protein bound: 99% (roflumilast); 97% (N-oxide metabolite)
Metabolism
Extensively metabolized by cytochrome P450, then it undergoes conjugation
Elimination
Half-life (topical): 4 days (roflumilast); 4.6 days (N-oxide metabolite)
Plasma clearance (IV): 9.6 L/hr
Administration
Topical Administration
For topical use only
Not for ophthalmic, oral, or intravaginal use
Wash hands after application, unless application is for treatment of hands
Storage
Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.